|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2008-10-2
|
|
pubmed:abstractText |
Incretin enhancers are a new class of antidiabetic drugs with promising therapeutic potential for type 2 diabetes. Therapeutic intervention in prediabetes is an attractive strategy for preventing or delaying diabetes onset. The aim of the present study was to investigate the therapeutic effects of incretin enhancement on incipient impaired glucose tolerance (iIGT) and manifest IGT (mIGT) using the dipeptidyl peptidase IV (DPP-4) inhibitor P32/98- and fatty Zucker rat (ZR, fa/fa) as a model.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Dipeptidyl-Peptidase IV Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Fatty Acids, Nonesterified,
http://linkedlifedata.com/resource/pubmed/chemical/Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Incretins,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Isoleucine,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides,
http://linkedlifedata.com/resource/pubmed/chemical/isoleucyl-thiazolidide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1463-1326
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
850-61
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17970756-Animals,
pubmed-meshheading:17970756-Blood Glucose,
pubmed-meshheading:17970756-Body Weight,
pubmed-meshheading:17970756-Dipeptidyl-Peptidase IV Inhibitors,
pubmed-meshheading:17970756-Fatty Acids, Nonesterified,
pubmed-meshheading:17970756-Glucose,
pubmed-meshheading:17970756-Glucose Intolerance,
pubmed-meshheading:17970756-Incretins,
pubmed-meshheading:17970756-Insulin,
pubmed-meshheading:17970756-Islets of Langerhans,
pubmed-meshheading:17970756-Isoleucine,
pubmed-meshheading:17970756-Male,
pubmed-meshheading:17970756-Models, Animal,
pubmed-meshheading:17970756-Obesity,
pubmed-meshheading:17970756-Rats,
pubmed-meshheading:17970756-Rats, Zucker,
pubmed-meshheading:17970756-Thiazoles,
pubmed-meshheading:17970756-Time Factors,
pubmed-meshheading:17970756-Tissue Culture Techniques,
pubmed-meshheading:17970756-Triglycerides
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance.
|
|
pubmed:affiliation |
Institute of Diabetes 'Gerhardt Katsch', Karlsburg, Germany. augstein@diabetes-karlsburg.de
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
